National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost-effectiveness of eltrombopag (Revolade®) for the treatment of chronic immune thrombocytopenic purpura (ITP).

Pharmacoeconomic Evaluation

Commenced Completed Outcome
30/07/2010 05/11/2010 Reimbursement not recommended.

The review group do not recommend the reimbursement of eltrombopag under the High Tech Drug scheme.

Eltrombopag (Revolade®) summary

A new rapid review was commissioned by the HSE in December 2017
Rapid review commissioned 04/12/2017
Rapid review completed 16/04/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies.